Close this search box.

The U.S. FDA Approves Johnson & Johnson’s Treatment for Blood Cancer

Blood Cancer

Treatment for Blood Cancer

The Food and Drug Administration (FDA) has authorized Johnson & Johnson’s medicine for treating multiple myeloma, the firm announced on Tuesday, providing patients with the incurable blood disease another therapeutic choice.

According to the company, J&J’s teclistamab, marketed as Tecvayli, is authorized for treating individuals with multiple myeloma that is difficult to treat or has returned after receiving four or more prior lines of specific types of treatments.

According to the company’s representative, the treatment for Blood Cancer, which will be accessible on or around November 4, will have a list price of $39,500 each month, with overall pricing ranging between $355,000 and $395,000.

Tecvayli is a bispecific antibody designed to drive the body’s immune system toward recognizing and killing cancer cells. It is the first medicine of its kind to be licensed to treat multiple myeloma.



Copyright 2023 © Insightscare Magazine ( a Digital Ink brand ) All rights reserved.